

# NATIONAL QUALITY FORUM

## Measure Submission and Evaluation Worksheet 5.0

This form contains the information submitted by measure developers/stewards, organized according to NQF's measure evaluation criteria and process. The evaluation criteria, evaluation guidance documents, and a blank online submission form are available on the [submitting standards web page](#).

NQF #: 0574	NQF Project: <a href="#">Renal Endorsement Maintenance 2011</a>
(for Endorsement Maintenance Review)	
Original Endorsement Date: <a href="#">Dec 04, 2009</a> Most Recent Endorsement Date: <a href="#">Dec 04, 2009</a>	
BRIEF MEASURE INFORMATION	
De.1 Measure Title: <a href="#">CHRONIC KIDNEY DISEASE (CKD): MONITORING CALCIUM</a>	
Co.1.1 Measure Steward: <a href="#">IMS Health</a>	
De.2 Brief Description of Measure: <a href="#">To ensure that members with chronic kidney disease (CKD), but who are not on dialysis, are monitored for blood calcium levels at least annually.</a>	
2a1.1 Numerator Statement: <a href="#">Members who received a calcium level blood test during the measurement year.</a>	
2a1.4 Denominator Statement: <a href="#">Members with at least 1 inpatient diagnosis of chronic kidney disease during the year prior to the measurement year or members with at least 2 diagnoses of chronic kidney disease in an outpatient setting during the measurement year or year prior (at least 1 of which must be during the year prior to the measurement year).</a>	
Time Window: <a href="#">The year prior to the measurement year.</a>	
2a1.8 Denominator Exclusions: <a href="#">Members who are on dialysis or in hospice during the measurement year. Members who were hospitalized during the numerator time frame and did not fulfill numerator criteria.</a>	
1.1 Measure Type: <a href="#">Process</a>	
2a1. 25-26 Data Source: <a href="#">Administrative claims</a>	
2a1.33 Level of Analysis: <a href="#">Clinician : Group/Practice, Clinician : Individual, Clinician : Team, Health Plan</a>	
1.2-1.4 Is this measure paired with another measure? <a href="#">No</a>	
De.3 If included in a composite, please identify the composite measure ( <i>title and NQF number if endorsed</i> ): <a href="#">N/A</a>	

STAFF NOTES ( <i>issues or questions regarding any criteria</i> )
Comments on Conditions for Consideration:
Is the measure untested? Yes <input type="checkbox"/> No <input type="checkbox"/> If untested, explain how it meets criteria for consideration for time-limited endorsement:
1a. Specific national health goal/priority identified by DHHS or NPP addressed by the measure ( <i>check De.5</i> ): 5. Similar/related <a href="#">endorsed</a> or submitted measures ( <i>check 5.1</i> ): Other Criteria:
Staff Reviewer Name(s):

1. IMPACT, OPPORTUNITY, EVIDENCE - IMPORTANCE TO MEASURE AND REPORT
Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All three subcriteria must be met to pass this criterion. See <a href="#">guidance on evidence</a> .

*Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)*

1a. High Impact: H  M  L  I

(The measure directly addresses a specific national health goal/priority identified by DHHS or NPP, or some other high impact aspect of healthcare.)

De.4 Subject/Topic Areas (Check all the areas that apply): Renal : Chronic Kidney Disease (CKD)

De.5 Cross Cutting Areas (Check all the areas that apply): Population Health

1a.1 Demonstrated High Impact Aspect of Healthcare: A leading cause of morbidity/mortality, Patient/societal consequences of poor quality

1a.2 If "Other," please describe:

1a.3 Summary of Evidence of High Impact (Provide epidemiologic or resource use data):

Approximately 26 million people in the US have chronic kidney disease (CKD)[1]. More than 6 million Americans have significant reductions in kidney function and nearly 400,000 require dialysis.[2] CKD patients account for 27.6% of general Medicare expenditure.[3, 4] In addition, an estimated 80,000 people are diagnosed annually with CKD.[5,6] Nearly all members with CKD would present with osteodystrophy, a disorder of bone remodeling, without appropriate monitoring and treatment for imbalances in calcium phosphate homeostatis.[7,8]

1a.4 Citations for Evidence of High Impact cited in 1a.3: 1. Facts about Chronic Kidney Disease. 2008 [cited 2008 November 11, 2008]; Available from: <http://www.kidney.org/kidneyDisease/>.

2. NKF K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Guideline 13. Factors associated with loss of kidney function in chronic kidney disease. , National kidney foundation. [http://www.kidney.org/professionals/doqi/kdoqi/p7\\_risk\\_g13.htm](http://www.kidney.org/professionals/doqi/kdoqi/p7_risk_g13.htm). Accessed June 1, 2004.

3. (2007) U.S. Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007. [http://www.usrds.org/2007/pdf/00a\\_precis\\_07.pdf](http://www.usrds.org/2007/pdf/00a_precis_07.pdf). Volume,

4. USRDS 2004 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, in US Renal Data System. 2004: Bethesda, MD.

5. Jones, et al., Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis, 1998. 32(6): p. 992-9.

6. Young and E. W., An improved understanding of the causes of end-stage renal disease. Semin Nephrol, 1997. 17(3): p. 170-5.

7. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310:358-363, 1995

8. Goodman WG, Coburn JW: The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 43:227-237, 1992

1b. Opportunity for Improvement: H  M  L  I

(There is a demonstrated performance gap - variability or overall less than optimal performance)

1b.1 Briefly explain the benefits (improvements in quality) envisioned by use of this measure:

Bone mineral disorders are common in patients with chronic kidney disease, and have potential for severe adverse impact on both mortality and morbidity. The diagnosis of bone mineral disorders is dependent on laboratory testing of calcium, phosphorus, and parathyroid hormone. This measure assesses the lowest rate of calcium measurement in patients with CKD, as advocated by national guidelines. Thus, the use of this measure would increase physician compliance with quality of care in the management of bone mineral disorders among patients with CKD and allow for identification of bone mineral disorders and referral of patients for appropriate treatment.

1b.2 Summary of Data Demonstrating Performance Gap (Variation or overall less than optimal performance across providers):

[For Maintenance – Descriptive statistics for performance results for this measure - distribution of scores for measured entities by quartile/decile, mean, median, SD, min, max, etc.]

A 2007 study examining adherence within a managed care setting to the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines found that the percentages of patients with Stage 3, Stage 4 and Stage 5 CKD who received AT LEAST annual calcium

testing were 90.8% 94.8% and 93.0%, respectively.[1] However, a 2008 study conducted on a privately insured population found that rates of serum calcium testing were significantly higher among those seen by nephrologists, as compared to internists (97.6%, vs 82.4%, P=0.008).[2]

Another study conducted on Medicaid patients with CKD, who had not yet begun dialysis, found that calcium testing levels were also high among this sub population but varied by comorbidity. Those with diabetes were significantly more likely to have calcium testing prior to initiation of dialysis than those without diabetes 95% vs 82% (p<0.0001).[3]

**1b.3 Citations for Data on Performance Gap: [For Maintenance – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]**

1. Hoy, et al., Adherence to K/DOQI practice guidelines for bone metabolism and disease. Am J Manag Care, 2007. 13(11): p. 620-5.
2. Philipneri, et al., Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. Clin Exp Nephrol, 2008. 12(1): p. 41-52.
3. Kausz, et al., General medical care among patients with chronic kidney disease: opportunities for improving outcomes. J Am Soc Nephrol, 2005. 16(10): p. 3092-101.

**1b.4 Summary of Data on Disparities by Population Group: [For Maintenance –Descriptive statistics for performance results for this measure by population group]**

Little research has been done regarding receipt of KDoQI guidelines among disadvantaged groups. However, it has been reported that women, non-diabetics and those being treated by an internist (rather than a nephrologist) may be less likely to receive appropriate monitoring.[1,2]

**1b.5 Citations for Data on Disparities Cited in 1b.4: [For Maintenance – Description of the data or sample for measure results reported in 1b.4 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]**

1. Philipneri, et al., Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. Clin Exp Nephrol, 2008. 12(1): p. 41-52.
2. Kausz, et al., General medical care among patients with chronic kidney disease: opportunities for improving outcomes. J Am Soc Nephrol, 2005. 16(10): p. 3092-101.

**1c. Evidence (Measure focus is a health outcome OR meets the criteria for quantity, quality, consistency of the body of evidence.)**  
 Is the measure focus a health outcome? Yes  No  **If not a health outcome, rate the body of evidence.**

Quantity: H  M  L  I  Quality: H  M  L  I  Consistency: H  M  L  I

Quantity	Quality	Consistency	Does the measure pass subcriterion1c?
M-H	M-H	M-H	Yes <input type="checkbox"/>
L	M-H	M	Yes <input type="checkbox"/> IF additional research unlikely to change conclusion that benefits to patients outweigh harms: otherwise No <input type="checkbox"/>
M-H	L	M-H	Yes <input type="checkbox"/> IF potential benefits to patients clearly outweigh potential harms: otherwise No <input type="checkbox"/>
L-M-H	L-M-H	L	No <input type="checkbox"/>

Health outcome – rationale supports relationship to at least one healthcare structure, process, intervention, or service	Does the measure pass subcriterion1c? Yes <input type="checkbox"/> IF rationale supports relationship
--	--

**1c.1 Structure-Process-Outcome Relationship (Briefly state the measure focus, e.g., health outcome, intermediate clinical outcome, process, structure; then identify the appropriate links, e.g., structure-process-health outcome; process- health outcome; intermediate clinical outcome-health outcome):**

This measure assesses the annual laboratory measurement of blood calcium levels in patients with chronic kidney disease. This is a process measure. The laboratory measurement of blood calcium is the first step in identifying patients with bone mineral disorders in need of treatment. In the medical literature there is direct relationship between aberrant levels of Ca, PO4 and PTH and disease.

**1c.2-3 Type of Evidence** (*Check all that apply*):

Clinical Practice Guideline

**1c.4 Directness of Evidence to the Specified Measure** (*State the central topic, population, and outcomes addressed in the body of evidence and identify any differences from the measure focus and measure target population*):

The patient population addressed by measure is patients with chronic kidney disease without dialysis, and there are no differences between the measure focus and measure target population.

**1c.5 Quantity of Studies in the Body of Evidence** (*Total number of studies, not articles*): There are numerous studies showing aberrancy of Ca, PO<sub>4</sub>, and PTH measurements starting at chronic kidney disease level three (Levin et al *Kidney Int* 2007, Melamed ML et al *Nephrol Dial Transplant* 2008). There are no studies indicating the appropriate frequency in which measurements of Ca, PO<sub>4</sub>, or PTH should be followed in chronic kidney disease. The evidence regarding the frequency of measurements of Ca, PO<sub>4</sub> or PTH is based on expert opinion.

**1c.6 Quality of Body of Evidence** (*Summarize the certainty or confidence in the estimates of benefits and harms to patients across studies in the body of evidence resulting from study factors. Please address: a) study design/flaws; b) directness/indirectness of the evidence to this measure (e.g., interventions, comparisons, outcomes assessed, population included in the evidence); and c) imprecision/wide confidence intervals due to few patients or events*): There are numerous cross-sectional studies showing aberrancy of Ca, PO<sub>4</sub>, and PTH measurements starting at chronic kidney disease level there (Levin et al *Kidney Int* 2007, Melamed ML et al *Nephrol Dial Transplant* 2008). Usually the best data to guide diagnostic monitoring is obtained from cross-sectional population-based or cohort-based studies. There are no studies indicating the appropriate frequency in which measurements of Ca, PO<sub>4</sub>, or PTH should be followed in chronic kidney disease.

**1c.7 Consistency of Results across Studies** (*Summarize the consistency of the magnitude and direction of the effect*): Studies show that, although changes in Ca, PO<sub>4</sub>, and PTH begin in CKD stage 3, the rate and magnitude of these changes are highly variable among different patients.

**1c.8 Net Benefit** (*Provide estimates of effect for benefit/outcome; identify harms addressed and estimates of effect; and net benefit - benefit over harms*):

The benefit of laboratory monitoring of Ca, PO<sub>4</sub>, and PTH would be timely diagnosis of metabolic bone disease. The harm of a laboratory blood draw is minimal.

**1c.9 Grading of Strength/Quality of the Body of Evidence.** Has the body of evidence been graded? **Yes**

**1c.10 If body of evidence graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias:** The recommendation for laboratory monitoring of Ca, PO<sub>4</sub>, and PTH was graded by the National Kidney Foundation (NKF) and Kidney Disease Improving Global Outcome (KDIGO).

**1c.11 System Used for Grading the Body of Evidence:** Other

**1c.12 If other, identify and describe the grading scale with definitions:** The National Kidney Foundation categorized their statements as "Evidence" or "Opinion". "Evidence" statements are backed by studies, and "Opinion" statements are based on expert consensus.

Kidney Disease Improving Global Outcome (KDIGO) grade the strength of their statements based on four factors: balance between desirable and undesirable effects, quality of the evidence, value and preferences, and cost. KDIGO assigns a number and a letter to their consensus statements. Letter grade "A" statements are of high quality, "B" statements are of moderate quality, "C" statements are of low quality and "D" statements are of very low quality. The numeric grade gives the strength of recommendation. Level 1 grade means that, from the patient perspective, "Most people in your situation would want the recommended course of action and only a small proportion would not" and from the clinician perspective "Most patients should receive the recommended course of action." Level 2 grade means that, from the patient perspective, "The majority of people in your situation would want the recommended course of action, but many would not", and from the clinician perspective, "Different choices will be appropriate for different patients. Each patient needs help to arrive at a management decision consistent with her or his values and preferences."

**1c.13 Grade Assigned to the Body of Evidence:** The NKF graded the body of evidence for CA, PO<sub>4</sub> and PTH monitoring starting in stage III kidney disease as “evidence” and frequency of measurement as “opinion”. KDIGO graded the body of evidence for CA, PO<sub>4</sub> and PTH monitoring starting in stage III kidney disease as “1 C”. Although KDIGO graded the evidence of this statement as “Low quality evidence”, KDIGO gave this statement a level 1 recommendation implying that “most patients should receive the recommended course of action”. KDIGO did not grade the frequency of measurement.

**1c.14 Summary of Controversy/Contradictory Evidence:** There was no contradictory evidence in the literature.

**1c.15 Citations for Evidence other than Guidelines (Guidelines addressed below):**

1. Philipneri, et al., Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. Clin Exp Nephrol, 2008. 12(1): p. 41-52.
2. Facts about Chronic Kidney Disease. 2008 [cited 2008 November 11, 2008]; Available from: <http://www.kidney.org/kidneyDisease/>. This measure is important because it assists in the identification and appropriate treatment abnormal calcium and phosphorus homeostatis at an early stage of chronic kidney disease before the harmful effects take place (i.e., hyperparathyroidism, osteodystrophy, calciphylaxis).

**1c.16 Quote verbatim, the specific guideline recommendation (Including guideline # and/or page #):**

National Kidney Foundation

1.1 Serum levels of calcium, phosphorus, and intact plasma parathyroid hormone(PTH) should be measured in all patients with CKD and GFR <60 mL/min/1.73 m<sup>2</sup>. (EVIDENCE) The frequency of these measurements should be based on the stage of chronic kidney disease (Table 14). (OPINION)

[Table indicated stage 3 CKD or more should be tested at least annually.] (Pg S52)

KDIGO Clinical Practice Guideline

3.1.1 We recommend monitoring serum levels of calcium, phosphorus, PTH, and alkaline phosphatase activity beginning in CKD stage 3 (1C). In children, we suggest such monitoring beginning in CKD stage 2 (2D). (page 523)

3.1.2 In patients with CKD stages 3–5D, it is reasonable to base the frequency of monitoring serum calcium, phosphorus, and PTH on the presence and magnitude of abnormalities, and the rate of progression of CKD (not graded).

Reasonable monitoring intervals would be:

In CKD stage 3: for serum calcium and phosphorus, every 6–12 months; (pg 525)

**1c.17 Clinical Practice Guideline Citation:** NKF K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Guideline 13. Factors associated with loss of kidney function in chronic kidney disease. National kidney foundation. [http://www.kidney.org/professionals/doqi/kdoqi/p7\\_risk\\_g13.htm](http://www.kidney.org/professionals/doqi/kdoqi/p7_risk_g13.htm).

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl, 2009(113)

**1c.18 National Guideline Clearinghouse or other URL:** N/A

**1c.19 Grading of Strength of Guideline Recommendation.** Has the recommendation been graded? No

**1c.20 If guideline recommendation graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias:**

**1c.21 System Used for Grading the Strength of Guideline Recommendation:** Other

**1c.22 If other, identify and describe the grading scale with definitions:** N/A

**1c.23 Grade Assigned to the Recommendation:** N/A

**1c.24 Rationale for Using this Guideline Over Others:** The National Kidney Foundation is a highly regarded organization whose guidelines are well respected within the medical community.

Based on the NQF descriptions for rating the evidence, what was the developer’s assessment of the quantity, quality, and

consistency of the body of evidence?  
 1c.25 Quantity: [High](#) 1c.26 Quality: [High](#) 1c.27 Consistency: [High](#)

Was the threshold criterion, *Importance to Measure and Report*, met?  
 (1a & 1b must be rated moderate or high and 1c yes) Yes  No   
 Provide rationale based on specific subcriteria:

**For a new measure if the Committee votes NO, then STOP.**  
**For a measure undergoing endorsement maintenance, if the Committee votes NO because of 1b. (no opportunity for improvement), it may be considered for continued endorsement and all criteria need to be evaluated.**

**2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES**

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (**evaluation criteria**)

Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. Testing information and results should be entered in the appropriate field. Supplemental materials may be referenced or attached in item 2.1. See [guidance on measure testing](#).

S.1 **Measure Web Page** (*In the future, NQF will require measure stewards to provide a URL link to a web page where current detailed specifications can be obtained*). Do you have a web page where current detailed specifications for this measure can be obtained? [No](#)

S.2 If yes, provide web page URL:

2a. RELIABILITY. Precise Specifications and Reliability Testing: H  M  L  I

2a1. Precise Measure Specifications. (*The measure specifications precise and unambiguous.*)

2a1.1 **Numerator Statement** (*Brief, narrative description of the measure focus or what is being measured about the target population, e.g., cases from the target population with the target process, condition, event, or outcome*):  
[Members who received a calcium level blood test during the measurement year.](#)

2a1.2 **Numerator Time Window** (*The time period in which the target process, condition, event, or outcome is eligible for inclusion*):  
[The measurement year.](#)

2a1.3 **Numerator Details** (*All information required to identify and calculate the cases from the target population with the target process, condition, event, or outcome such as definitions, codes with descriptors, and/or specific data collection items/responses*):  
[Numberator Logic: A only](#)

[\[A\] Members who received a calcium level blood test during the measurement year.](#)

CPT-4 code(s): [80047, 80048, 80050, 80053, 80069, 80410, 82310, 82330, 82331](#)

CPT-4 category II code(s): [3278F](#)

2a1.4 **Denominator Statement** (*Brief, narrative description of the target population being measured*):  
[Members with at least 1 inpatient diagnosis of chronic kidney disease during the year prior to the measurement year or members with at least 2 diagnoses of chronic kidney disease in an outpatient setting during the measurement year or year prior \(at least 1 of which must be during the year prior to the measurement year\).](#)

[Time Window: The year prior to the measurement year.](#)

2a1.5 **Target Population Category** (*Check all the populations for which the measure is specified and tested if any*): [Adult/Elderly Care](#)

2a1.6 **Denominator Time Window** (*The time period in which cases are eligible for inclusion*):

The year prior to the measurement year.

**2a1.7 Denominator Details** (All information required to identify and calculate the target population/denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):

Denominator Logic: (A or (B and C) or D) and CE

[CE] Members continuously enrolled during the measurement year.

[A] Members with at least 1 inpatient encounter with chronic renal disease (Stage >= 3) during the year prior to the measurement year.

Chronic Renal Disease:

ICD-9 diagnosis code(s): 250.4x, 274.1x, 403.01, 403.11, 403.90, 403.91, 404.02, 404.03, 404.10, 404.11, 404.12, 404.13, 404.90, 404.91, 404.92, 404.93, 581.xx, 582.xx, 583.xx, 585.3-585.5, 586, 587, 588.xx, 753.0, 753.10, 753.11, 753.12, 753.13, 753.14, 753.15, 753.16, 753.17, 753.19

DRG code(s): 316

MS-DRG code(s): 682-684

AND

Inpatient setting:

CPT-4 code(s): 99221-99223, 99231-99233, 99238-99239, 99251-99255, 99261\*-99263\*, 99291-99300, 99356-99357, 99431\*-99440\*, 99460-99465, 99468-99476, 99477-99480

UB revenue code(s): 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x-022x, 072x, 080x, 0987

[B] Members with at least 1 face-to-face outpatient encounter with chronic kidney disease (stage >= 3) during the year prior to the measurement year.

Chronic Renal Disease:

ICD-9 diagnosis code(s): 250.4x, 274.1x, 403.01, 403.11, 403.90, 403.91, 404.02, 404.03, 404.10, 404.11, 404.12, 404.13, 404.90, 404.91, 404.92, 404.93, 581.xx, 582.xx, 583.xx, 585.3-585.5, 586, 587, 588.xx, 753.0, 753.10, 753.11, 753.12, 753.13, 753.14, 753.15, 753.16, 753.17, 753.19

DRG code(s): 316

MS-DRG code(s): 682-684

AND

Outpatient setting:

CPT-4 code(s): 99201-99205, 99211-99215, 99241-99245, 99271\*-99275\*, 99301\*-99303\*, 99304-99310, 99311\*-99313\*, 99315-99316, 99318-99337, 99341-99350, 99354-99355, 99381-99387, 99391-99397, 99401-99429, 99450, 99455-99456

UB revenue code(s): 051x, 0520-0523, 0526-0529, 057x-059x, 077x, 082x-085x, 088x, 0982-0983

Hospital observation:

CPT-4 code(s): 99217-99220, 99234-99236

[C] Members with at least 1 face-to-face outpatient encounter with chronic kidney disease (stage >= 3) during the measurement year.

Chronic kidney disease:

ICD-9 diagnosis code(s): 250.4x, 274.1x, 403.01, 403.11, 403.90, 403.91, 404.02, 404.03, 404.10, 404.11, 404.12, 404.13, 404.90, 404.91, 404.92, 404.93, 581.xx, 582.xx, 583.xx, 585.3-585.5, 586, 587, 588.xx, 753.0, 753.10-753.17, 753.19

DRG code(s): 316

MS-DRG code(s): 682-684

AND

Outpatient setting:

CPT-4 code(s): 99201-99205, 99211-99215, 99241-99245, 99271\*-99275\*, 99301\*-99303\*, 99304-99310, 99311\*-99313\*, 99315-99316, 99318-99337, 99341-99350, 99354-99355, 99366, 99381-99387, 99391-99397, 99401-99429, 99450, 99455-99456

UB revenue code(s): 051x, 0520-0523, 0526-0529, 057x-059x, 077x, 082x-085x, 088x, 0982, 0983

NQF #0574 CHRONIC KIDNEY DISEASE (CKD): MONITORING CALCIUM

Hospital observation:

CPT-4 code(s): 99217-99220, 99234-99236

[D] Members with at least 2 face-to-face outpatient encounters (on different dates of service) with chronic kidney disease (stage >= 3) during the year prior to measurement year.

Chronic kidney disease:

ICD-9 diagnosis code(s): 250.4x, 274.1x, 403.01, 403.11, 403.90, 403.91, 404.02, 404.03, 404.10, 404.11, 404.12, 404.13, 404.90, 404.91, 404.92, 404.93, 581.xx, 582.xx, 583.xx, 585.3-585.5, 586, 587, 588.xx, 753.0, 753.10-753.17, 753.19

DRG code(s): 316

MS-DRG code(s): 682-684

AND

Outpatient setting:

CPT-4 code(s): 99201-99205, 99211-99215, 99241-99245, 99271\*-99275\*, 99301\*-99303\*, 99304-99310, 99311\*-99313\*, 99315-99316, 99318-99337, 99341-99350, 99354-99355, 99366, 99381-99387, 99391-99397, 99401-99429, 99450, 99455-99456

UB revenue code(s): 051x, 0520-0523, 0526-0529, 057x-059x, 077x, 082x-085x, 088x, 0982, 0983

Hospital observation:

CPT-4 code(s): 99217-99220, 99234-99236

\*Code range was retired but is still appropriate for retrospective analysis.

**2a1.8 Denominator Exclusions** *(Brief narrative description of exclusions from the target population):*

Members who are on dialysis or in hospice during the measurement year. Members who were hospitalized during the numerator time frame and did not fulfill numerator criteria.

**2a1.9 Denominator Exclusion Details** *(All information required to identify and calculate exclusions from the denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):*

Members who are on dialysis or in hospice during the measurement year. Members who were hospitalized during the numerator time frame and did not fulfill numerator criteria.

Denominator Exclusion Logic: A or B or (C and NOT Numerator Criteria A)

[A] Members on dialysis or who utilized dialysis during the measurement year.

ICD-9 diagnosis code(s): 458.21, 585.6, 792.5, 996.56, 996.62, 996.68, 996.73, E870.2, E874.2, E879.1, V45.1x, V56.xx

ICD-9 surgical proc code(s): 38.95, 39.27, 39.42, 39.93, 39.95, 54.98

DRG code: 317

CPT code(s): 0505F, 0507F, 3066F, 3082F-3084F, 4051F-4055F, 36147, 36148, 36800, 36810, 36815, 36818-36821, 36825, 36830-36833, 36838, 36870, 49421, 75790\*, 75791, 90920, 90921, 90924, 90925, 90935, 90937, 90939\*, 90940, 90945, 90947, 90951-90999

HCPCS: A4653, A4671-A4918, E1500-E1699, G0257, G0314-G0319, G0322, G0323, G0326, G0327, G8075, G8076, G9013, G9014

UB revenue code(s): 0304, 0800-0809, 0820-0859, 0880, 0881-0889

DRG code: 317

MS-DRG code(s): 685

[B] Members who were in hospice care during the measurement year.

ICD-9 diagnosis code(s): V66.7

CPT-4 code(s): 99376\*, 99377, 99378

HCPCS code(s): G0065\*, G0182, G0337, Q5001-Q5009, S0271, S9126, T2042-T2046

UB revenue code(s): 0115, 0125, 0135, 0145, 0155, 0235, 0650-0652, 0655-0659

UB type of bill code(s): 81x, 82x

Place of service code(s): 34

[C] Members who had an inpatient stay during the measurement year.

Inpatient setting:

CPT-4 code(s): 99221-99223, 99231-99233, 99238-99239, 99251-99255, 99261\*-99263\*, 99291-99300, 99356-99357, 99431\*-99440\*, 99460-99465, 99468-99476, 99477-99480

UB revenue code(s): 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x-022x, 072x, 080x, 0987

**2a1.10 Stratification Details/Variables** (All information required to stratify the measure results including the stratification variables, codes with descriptors, definitions, and/or specific data collection items/responses):

N/A

**2a1.11 Risk Adjustment Type** (Select type. Provide specifications for risk stratification in 2a1.10 and for statistical model in 2a1.13): **No risk adjustment or risk stratification** 2a1.12 If "Other," please describe:

**2a1.13 Statistical Risk Model and Variables** (Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development should be addressed in 2b4.):

N/A

**2a1.14-16 Detailed Risk Model Available at Web page URL** (or attachment). Include coefficients, equations, codes with descriptors, definitions, and/or specific data collection items/responses. Attach documents only if they are not available on a webpage and keep attached file to 5 MB or less. NQF strongly prefers you make documents available at a Web page URL. Please supply login/password if needed:

**2a1.17-18. Type of Score:** [Rate/proportion](#)

**2a1.19 Interpretation of Score** (Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score): [Better quality = Higher score](#)

**2a1.20 Calculation Algorithm/Measure Logic**(Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.):

The first step in calculating a performance score utilizing this measure is to identify the denominator, or patients with chronic kidney disease. Next, excluded patients are removed from the denominator; exclusions for this measure include patients on dialysis or hospice as well as patients who were hospitalized during the numerator timeframe and did not fulfill the numerator criteria. Next, the numerator, or the rate of calcium measurement, can be determined. Calculating the numerator/denominator ratio provides the rate for a health plan, provider, etc. As this is a process measure, there is no risk adjustment necessary.

**2a1.21-23 Calculation Algorithm/Measure Logic Diagram URL or attachment:**

**2a1.24 Sampling (Survey) Methodology.** If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):

N/A

**2a1.25 Data Source** (Check all the sources for which the measure is specified and tested). If other, please describe:

[Administrative claims](#)

**2a1.26 Data Source/Data Collection Instrument** (Identify the specific data source/data collection instrument, e.g. name of

database, clinical registry, collection instrument, etc.): [Member demographics and member enrollment data](#)

2a1.27-29 Data Source/data Collection Instrument Reference Web Page URL or Attachment:

2a1.30-32 Data Dictionary/Code Table Web Page URL or Attachment:

2a1.33 Level of Analysis (Check the levels of analysis for which the measure is specified and tested): [Clinician : Group/Practice](#), [Clinician : Individual](#), [Clinician : Team](#), [Health Plan](#)

2a1.34-35 Care Setting (Check all the settings for which the measure is specified and tested): [Ambulatory Care : Clinic/Urgent Care](#), [Ambulatory Care : Clinician Office](#), [Laboratory](#)

2a2. Reliability Testing. (Reliability testing was conducted with appropriate method, scope, and adequate demonstration of reliability.)

2a2.1 Data/Sample (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

Data from commercial health plans were used to generate rates of serum calcium testing. Included health plans range from 3 to 7 million members.

2a2.2 Analytic Method (Describe method of reliability testing & rationale):

Testing rates for Plans A and B were compared for stability over the course of two years. Plan A consisted of data from 2008 and 2009. For Plan B, year one included data from 7/1/08 to 6/30/09 and year two consisted of data from 7/1/09 to 6/30/10.

2a2.3 Testing Results (Reliability statistics, assessment of adequacy in the context of norms for the test conducted):

PLAN	Year 1 Rate	Year 2 Rate	Year 1 Denominator	Year 2 Denominator	PLAN	Year 1 Rate	Year 2 Rate	Year 1 Denominator	Year 2 Denominator
Plan A	89.01%	89.76%	7258	7760	Plan B	90.80%	91.00%	8552	8776

2b. VALIDITY. Validity, Testing, including all Threats to Validity: H  M  L  I

2b1.1 Describe how the measure specifications (measure focus, target population, and exclusions) are consistent with the evidence cited in support of the measure focus (criterion 1c) and identify any differences from the evidence:

The patient population addressed by measure is patients with chronic kidney disease, not on dialysis; there are no differences between the measure focus and measure target population. Both the measure focus and target population are consistent with the evidence.

2b2. Validity Testing. (Validity testing was conducted with appropriate method, scope, and adequate demonstration of validity.)

2b2.1 Data/Sample (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

2008 Data from six geographically diverse commercial health plans were used to generate rates of serum calcium testing. The sizes of the included health plans range from 580,000 members, to 7 million members.

2b2.2 Analytic Method (Describe method of validity testing and rationale; if face validity, describe systematic assessment):

PART 1: The algorithm for serum calcium testing was run on all six plans. Denominator size and rate were calculated for each plan.

PART 2: Rates generated using this algorithm were compared to annual rates for serum calcium testing found in the literature.

2b2.3 Testing Results (Statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment):

PART 1:

PLAN	RATE	DENOMINATOR
------	------	-------------

Plan A	89.01%	7258
Plan B	90.80%	8552
Plan C	86.22%	646
Plan D	70.25%	13550
Plan E	88.84%	3153
Plan F	89.86%	5817

Average Rate: 85.83%, Standard Deviation: 7.78%  
 Average Denominator: 6496

**PART 2:**

Several U.S. based studies have examined prevalence of serum calcium testing among patients with CKD, and have reported testing rates between 60 and 95%. [1] However, these studies vary greatly by provider specialty (primary care vs nephrology), data source (chart review vs administrative claims), observation period, and kidney function of study cohort members.

Studies using chart review have reported rates of testing of 60%, 72%, 76% and 95% [2-5]. However, rates of testing in these samples do not seem to correlate well with specialty. [1]

However, studies based on administrative claims data appear to have more consistent results. In a sample of 519 patients with Phase 3, CKD, Philipneri et al found serum calcium testing rates of 82.4% within a year among those seen by primary care providers, vs 97.6% among those seen by nephrologists. [1] Another study that was specific to stage 3 CKD (n=424) patients demonstrated testing rates of 91%. [6] Similarly, a study based on 24,778 patients with CKD found testing serum calcium rates of 82% within 2 years prior to the start of dialysis. [7]

While a fair amount of variation was seen among health care plans on which this algorithm was tested, this variation fell well within the rates reported by the literature. Additionally, the average plan rate of 85.83% that we report is highly consistent with rates reported by other administrative claims-based studies.

1. Philipneri, et al., Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. Clin Exp Nephrol, 2008. 12(1): p. 41-52.
2. Israni, et al., Management of chronic kidney disease in an academic primary care clinic. Am J Nephrol, 2003. 23(1): p. 47-54.
3. Kausz, et al., Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol, 2001. 12(7): p. 1501-7.
4. Lafayette, et al., Examining chronic kidney disease management in a single center. Clin Nephrol, 2004. 62(4): p. 260-6.
5. Murray, et al., Delivery of predialysis care in an academic referral nephrology practice. Ren Fail, 2005. 27(5): p. 571-80.
6. Hoy, et al., Adherence to K/DOQI practice guidelines for bone metabolism and disease. Am J Manag Care. 2007 Nov;13(11):620-5.
7. Kausz, et al., General medical care among patients with chronic kidney disease: opportunities for improving outcomes. J Am Soc Nephrol, 2005. 16(10): p. 3092-101.

**POTENTIAL THREATS TO VALIDITY.** (*All potential threats to validity were appropriately tested with adequate results.*)

**2b3. Measure Exclusions.** (*Exclusions were supported by the clinical evidence in 1c or appropriately tested with results demonstrating the need to specify them.*)

**2b3.1 Data/Sample for analysis of exclusions** (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):

Data from a commercial health plan were used to generate rates of serum calcium testing. The data spanned from 7/1/09-6/30/10 and included a membership of 7 million members.

**2b3.2 Analytic Method** (*Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference*):

Using data from this plan, the rates and numbers of excluded patients were determined. Exclusions for this measure include patients on dialysis, in hospice, or those with an inpatient stay. We do not believe that a sensitivity analysis is relevant in this

situation, given that these exclusions were determined a priori based on clinical acumen and knowledge of administrative claims data.

**2b3.3 Results** (Provide statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses):  
Prior to exclusions, the denominator was 10192. Following the 3 exclusions, the denominator was 8776.

**2b4. Risk Adjustment Strategy.** (For outcome measures, adjustment for differences in case mix (severity) across measured entities was appropriately tested with adequate results.)

**2b4.1 Data/Sample** (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

N/A

**2b4.2 Analytic Method** (Describe methods and rationale for development and testing of risk model or risk stratification including selection of factors/variables):

N/A

**2b4.3 Testing Results** (Statistical risk model: Provide quantitative assessment of relative contribution of model risk factors; risk model performance metrics including cross-validation discrimination and calibration statistics, calibration curve and risk decile plot, and assessment of adequacy in the context of norms for risk models. Risk stratification: Provide quantitative assessment of relationship of risk factors to the outcome and differences in outcomes among the strata):

N/A

**2b4.4 If outcome or resource use measure is not risk adjusted, provide rationale and analyses to justify lack of adjustment:** This is a process measure, therefore, there is no need for risk-adjustment.

**2b5. Identification of Meaningful Differences in Performance.** (The performance measure scores were appropriately analyzed and discriminated meaningful differences in quality.)

**2b5.1 Data/Sample** (Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

The data utilized for this analysis were from a plan with approximately 7 million members. The sample included a final denominator of 8776 patients. The data spanned from 7/1/09 to 6/30/10.

**2b5.2 Analytic Method** (Describe methods and rationale to identify statistically significant and practically/meaningfully differences in performance):

In order to differentiate provider performance, we first identify individual providers and determine their rates. These individual rates can then be analyzed to determine mean rates, as well as the standard deviation. We can also divide the providers by quartile in order to determine the statistical significance of performance between quartiles.

**2b5.3 Results** (Provide measure performance results/scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance):

Total number of physicians with a denominator greater than 10: 709

Mean: 94.4%

Standard Deviation: 17.3

Range: 0-100%

Q1: 100%

Q3: 100%

The monitoring of mineral bone disease in patients with chronic kidney disease requires laboratory testing of Ca, PO<sub>4</sub>, and PTH. We note that the testing rate for Calcium is always the highest of the three. This is because the test for Calcium is found on basic metabolic panels. However, despite the ease of obtaining a Calcium test, there is still room for improvement.

**2b6. Comparability of Multiple Data Sources/Methods.** (If specified for more than one data source, the various approaches result in comparable scores.)

**2b6.1 Data/Sample** (Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

N/A. Administrative data is the only data source for this measure.

**2b6.2 Analytic Method** (Describe methods and rationale for testing comparability of scores produced by the different data sources specified in the measure):

N/A. Administrative data is the only data source for this measure.

**2b6.3 Testing Results** (Provide statistical results, e.g., correlation statistics, comparison of rankings; assessment of adequacy in the context of norms for the test conducted):

N/A. Administrative data is the only data source for this measure.

**2c. Disparities in Care:** H  M  L  I  NA  (If applicable, the measure specifications allow identification of disparities.)

**2c.1** If measure is stratified for disparities, provide stratified results (Scores by stratified categories/cohorts): N/A

**2c.2** If disparities have been reported/identified (e.g., in 1b), but measure is not specified to detect disparities, please explain:

N/A

**2.1-2.3 Supplemental Testing Methodology Information:**

**Steering Committee: Overall, was the criterion, *Scientific Acceptability of Measure Properties*, met?**  
(Reliability and Validity must be rated moderate or high) Yes  No

Provide rationale based on specific subcriteria:

**If the Committee votes No, STOP**

### 3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (**evaluation criteria**)

**C.1 Intended Purpose/ Use** (Check all the purposes and/or uses for which the measure is intended): **Public Reporting, Quality Improvement (Internal to the specific organization)**

**3.1 Current Use** (Check all that apply; for any that are checked, provide the specific program information in the following questions): **Quality Improvement (Internal to the specific organization)**

**3a. Usefulness for Public Reporting:** H  M  L  I

(The measure is meaningful, understandable and useful for public reporting.)

**3a.1. Use in Public Reporting - disclosure of performance results to the public at large** (If used in a public reporting program, provide name of program(s), locations, Web page URL(s)). If not publicly reported in a national or community program, state the reason AND plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement: [**For Maintenance** – If not publicly reported, describe progress made toward achieving disclosure of performance results to the public at large and expected date for public reporting; provide rationale why continued endorsement should be considered.]

This measure is designed to be used for public reporting and incentive-based performance programs. Our organization is not a health plan, and thus, is unable to implement a public reporting program. However, we are currently in discussions with various health plans to encourage the use of this measure for public reporting.

**3a.2. Provide a rationale for why the measure performance results are meaningful, understandable, and useful for public reporting.** If usefulness was demonstrated (e.g., focus group, cognitive testing), describe the data, method, and results: **Bone mineral disorders are common in patients with chronic kidney disease, and have the potential for severe adverse impact on both mortality and morbidity. The diagnosis of bone mineral disorders is dependent on laboratory testing of calcium, phosphorus, and**

parathyroid hormone levels. This measure reports the percentage of patients with chronic kidney disease who received the indicated quality of care. A higher score indicates higher quality of care. The construction of this measure is similar to many other well recognized and established measures (e.g., percent of diabetics who received Hba1c).

Public reporting of physicians' compliance on this measure would improve physician performance potentially through two pathways. In one pathway stakeholders, such as patients, consumers, purchasers, and health plans can compare provider performance via publicly released data for this measure and reward better performance with increased volume. In the second pathway, these data can assist medical groups or physicians to identify areas to target for improvement. Public reporting of physician compliance with this measure may also increase patient awareness of the importance of laboratory testing for calcium, phosphorus, and parathyroid hormone in the setting of chronic kidney disease.

**3.2 Use for other Accountability Functions (payment, certification, accreditation).** If used in a public accountability program, provide name of program(s), locations, Web page URL(s): *This measure is currently not being used in any of these capacities, although health plans have expressed interest in utilizing the measure for pay for performance.*

**3b. Usefulness for Quality Improvement:** H  M  L  I

*(The measure is meaningful, understandable and useful for quality improvement.)*

**3b.1. Use in QI.** If used in quality improvement program, provide name of program(s), locations, Web page URL(s):

**[For Maintenance –** *If not used for QI, indicate the reasons and describe progress toward using performance results for improvement].*

This measure is currently in use by BlueCross BlueShield of Alabama for quality improvement through their program, Physician Quality and Transparency Program. The results are posted on an internal website that allows the physicians to view their performance and see how it compares to other physicians within the plan.

The URL for this program is: <http://www.bcsal.org/providers/physicianqualityandtransparencyprogram/index.cfm>

**3b.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for quality improvement.** *If usefulness was demonstrated (e.g., QI initiative), describe the data, method and results:*

*In addition to reporting the percentage of patients with chronic kidney who received the indicated quality of care for this measure, IMS has developed an online tool (currently in use by several health plans) that allows physicians to view the names and medical records of patients who did not receive the indicated quality of care. This tool can aid physicians in their quality improvement efforts.*

**Overall, to what extent was the criterion, Usability, met?** H  M  L  I

**Provide rationale based on specific subcriteria:**

#### 4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. **(evaluation criteria)**

**4a. Data Generated as a Byproduct of Care Processes:** H  M  L  I

**4a.1-2 How are the data elements needed to compute measure scores generated?** *(Check all that apply).*

Data used in the measure are:

*Coded by someone other than person obtaining original information (e.g., DRG, ICD-9 codes on claims)*

**4b. Electronic Sources:** H  M  L  I

**4b.1 Are the data elements needed for the measure as specified available electronically** *(Elements that are needed to compute measure scores are in defined, computer-readable fields):* *ALL data elements in electronic claims*

**4b.2 If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources:**

**4c. Susceptibility to Inaccuracies, Errors, or Unintended Consequences:** H  M  L  I

**4c.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during**

testing and/or operational use and strategies to prevent, minimize, or detect. If audited, provide results:  
 This is an administrative claims-based quality indicator with certain potential biases, including coding variation between providers and missing data. Nevertheless, administrative claims data are widely available and have been used to effectively examine and document patterns of health care utilization, detect opportunities to improve quality of care, estimate incidence of disease, and even assess outcomes of pharmaceutical, radiological, and surgical procedures.

4d. Data Collection Strategy/Implementation: H  M  L  I

A.2 Please check if either of the following apply (regarding proprietary measures): [Proprietary measure](#)

4d.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues (e.g., fees for use of proprietary measures):

IMS Health has developed an online tool (currently in use by several health plans), which allows physicians the opportunity to supplement their quality scores through self-report via a secured web site. Via this website, physicians are able to identify specific patients with whom they had an office visit during the measurement period and who reportedly did not have the indicated quality care. Physicians can then review their charts to verify whether in fact the quality care was performed. The physician can then manually enter corrections to the patient record via the website, indicating that the quality care was done. This data is subject to clinical review prior to acceptance. The hybrid quality score (via administrative claims and self report) can be updated on a quarterly basis.

Overall, to what extent was the criterion, *Feasibility*, met? H  M  L  I

Provide rationale based on specific subcriteria:

### OVERALL SUITABILITY FOR ENDORSEMENT

Does the measure meet all the NQF criteria for endorsement? Yes  No

Rationale:

**If the Committee votes No, STOP.**

**If the Committee votes Yes, the final recommendation is contingent on comparison to related and competing measures.**

### 5. COMPARISON TO RELATED AND COMPETING MEASURES

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are compared to address harmonization and/or selection of the best measure before a final recommendation is made.

5.1 If there are related measures (either same measure focus or target population) or competing measures (both the same measure focus and same target population), list the NQF # and title of all related and/or competing measures:

0570 : CHRONIC KIDNEY DISEASE (CKD): MONITORING PHOSPHORUS

0571 : CHRONIC KIDNEY DISEASE (CKD): MONITORING PARATHYROID HORMONE (PTH)

#### 5a. Harmonization

5a.1 If this measure has EITHER the same measure focus OR the same target population as [NQF-endorsed measure\(s\)](#): Are the measure specifications completely harmonized?

5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden:

#### 5b. Competing Measure(s)

5b.1 If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s): Describe why this measure is superior to competing measures (e.g., a more valid or efficient way to measure quality); OR provide a rationale for the additive value of endorsing an additional measure. (Provide analyses when possible):

CONTACT INFORMATION
Co.1 Measure Steward (Intellectual Property Owner): <a href="#">IMS Health, 21650 Oxnard Street, Suite 1850, Woodland Hills, California, 91367</a>
Co.2 Point of Contact: <a href="#">Dan, Malloy, PhD, <a href="mailto:dmalloy@us.imshealth.com">dmalloy@us.imshealth.com</a>, 800-465-6575-</a>
Co.3 Measure Developer if different from Measure Steward: <a href="#">IMS Health, 21650 Oxnard Street, Suite 1850, Woodland Hills, California, 91367</a>
Co.4 Point of Contact: <a href="#">Irina, Yermilov, MD, MPHTM, <a href="mailto:iyermilov@us.imshealth.com">iyermilov@us.imshealth.com</a>, 818-676-2835-</a>
Co.5 Submitter: <a href="#">Irina, Yermilov, MD, MPHTM, <a href="mailto:iyermilov@us.imshealth.com">iyermilov@us.imshealth.com</a>, 818-676-2835-, IMS Health</a>
Co.6 Additional organizations that sponsored/participated in measure development: <a href="#">N/A</a>
Co.7 Public Contact: <a href="#">Dan, Malloy, PhD, <a href="mailto:dmalloy@us.imshealth.com">dmalloy@us.imshealth.com</a>, 800-465-6575-, IMS Health</a>

ADDITIONAL INFORMATION
<p>Workgroup/Expert Panel involved in measure development</p> <p>Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development. <a href="#">N/A</a></p>
<p>Ad.2 If adapted, provide title of original measure, NQF # if endorsed, and measure steward. Briefly describe the reasons for adapting the original measure and any work with the original measure steward: <a href="#">N/A</a></p>
<p>Measure Developer/Steward Updates and Ongoing Maintenance</p> <p>Ad.3 Year the measure was first released: <a href="#">2008</a></p> <p>Ad.4 Month and Year of most recent revision: <a href="#">02, 2011</a></p> <p>Ad.5 What is your frequency for review/update of this measure? <a href="#">Yearly</a></p> <p>Ad.6 When is the next scheduled review/update for this measure? <a href="#">02, 2012</a></p>
<p>Ad.7 Copyright statement/disclaimers: <a href="#">©2011 IMS Health Incorporated or its affiliates. All Rights Reserved.</a></p>
<p>Ad.8 Additional Information/Comments:</p>
<p>Date of Submission (MM/DD/YY): <a href="#">06/08/2011</a></p>